- Home
- CROX vs NUVL Comparison
CROX vs NUVL Comparison
Compare CROX & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CROX
- NUVL
- Stock Information
- Founded
- CROX 1999
- NUVL 2017
- Country
- CROX United States
- NUVL United States
- Employees
- CROX N/A
- NUVL N/A
- Industry
- CROX Shoe Manufacturing
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- CROX Consumer Discretionary
- NUVL Health Care
- Exchange
- CROX Nasdaq
- NUVL Nasdaq
- Market Cap
- CROX 5.4B
- NUVL 5.6B
- IPO Year
- CROX 2006
- NUVL 2021
- Fundamental
- Price
- CROX $110.01
- NUVL $71.76
- Analyst Decision
- CROX Strong Buy
- NUVL Strong Buy
- Analyst Count
- CROX 12
- NUVL 8
- Target Price
- CROX $133.73
- NUVL $115.50
- AVG Volume (30 Days)
- CROX 1.7M
- NUVL 660.5K
- Earning Date
- CROX 05-08-2025
- NUVL 05-08-2025
- Dividend Yield
- CROX N/A
- NUVL N/A
- EPS Growth
- CROX 26.25
- NUVL N/A
- EPS
- CROX 16.31
- NUVL N/A
- Revenue
- CROX $4,100,808,000.00
- NUVL N/A
- Revenue This Year
- CROX $3.65
- NUVL N/A
- Revenue Next Year
- CROX $3.39
- NUVL N/A
- P/E Ratio
- CROX $6.78
- NUVL N/A
- Revenue Growth
- CROX 2.09
- NUVL N/A
- 52 Week Low
- CROX $86.11
- NUVL $55.54
- 52 Week High
- CROX $165.32
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- CROX 65.24
- NUVL 51.04
- Support Level
- CROX $98.14
- NUVL $63.56
- Resistance Level
- CROX $112.69
- NUVL $78.97
- Average True Range (ATR)
- CROX 3.72
- NUVL 3.30
- MACD
- CROX 2.00
- NUVL -0.20
- Stochastic Oscillator
- CROX 91.53
- NUVL 59.65
About CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company are the United States and other Countries.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.